Data as of Dec 26
| -0.13 / -0.30%|
The 29 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 49.68, with a high estimate of 58.92 and a low estimate of 40.40. The median estimate represents a +13.76% increase from the last price of 43.67.
The current consensus among 29 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.